How and where to order Bimatoprost (Latisse, Lumigan, Careprost) ophthalmic solution 0.03% 3 ml online:
LUMIGAN (BIMATOPROST) OPHTHALMIC SOLUTION 0.01% AND 0.03%: ADVERSE REACTIONS / SIDE EFFECTS (see "References")
Clinical Studies Experience
Because clinical studies of Lumigan (Bimatoprost) eye drops are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In clinical studies with Bimatoprost ophthalmic solutions 0.01% or 0.03% (Lumigan) the most common adverse event was conjunctival hyperemia (range 25% - 45%). Approximately 0.5% to 3% of patients discontinued therapy due to conjunctival hyperemia with 0.01% or 0.03% bimatoprost ophthalmic solutions. Other common events ( > 10%) included growth of eyelashes, and ocular pruritus.
Additional ocular adverse events (reported in 1 to 10% of patients) with bimatoprost ophthalmic solutions included visual disturbance, ocular dryness, ocular burning, eye pain, foreign body sensation, pigmentation of the periocular skin, cataract, blepharitis, superficial punctate keratitis, ocular irritation, eyelid erythema, eyelash darkening, tearing, eye discharge, photophobia, asthenopia, allergic conjunctivitis, increases in iris pigmentation, conjunctival hemorrhage, conjunctival edema, and abnormal hair growth. Intraocular inflammation, reported as iritis was reported in less than 1% of patients.
Systemic adverse events reported in approximately 10% of patients with bimatoprost ophthalmic solutions were infections (primarily colds and upper respiratory tract infections). Other systemic adverse events (reported in 1 to 5% of patients) included headaches, abnormal liver function tests, and asthenia.
Recent posts:
Lumigan prescribing information
|